Management of rheumatoid arthritis: summary of NICE guidance
نویسندگان
چکیده
Why read this summary? Rheumatoid arthritis is a chronic, progressive autoimmune disease associated with inflammation principally in synovial joints and affecting over 400 000 people in the United Kingdom. In recent years it has become clear that pain and disability can be avoided if the disease is recognised early and treated promptly and appropriately. It is therefore crucial that all health professionals have knowledge of the recognition, management, and appropriate referral of patients with rheumatoid arthritis. This article summarises the recommendations in the guideline from the National Institute for Health and Clinical Excellence (NICE) on the management of rheumatoid arthritis, from early identification to managing chronic and severe disease.
منابع مشابه
Association between NICE guidance on biologic therapies with rates of hip and knee replacement among rheumatoid arthritis patients in England and Wales: An interrupted time-series analysis.
OBJECTIVE To estimate the impact of NICE approval of tumor necrosis factor inhibitor (TNFi) therapies on the incidence of total hip replacement (THR) and total knee replacement (TKR) among rheumatoid arthritis (RA) patients in England and Wales. METHODS Primary care data [Clinical Practice Research Datalink (CPRD)] for the study period (1995-2014) were used to identify incident adult RA patie...
متن کاملComparative Measurement of Rheumatoid Factor in Serum and Synovial Fluid of Rheumatoid Arthritis Patients by ELISA and Latex-Agglutination Test
Rheumatoid factors (RF) are autoantibodies with specificity for the Fc portion of human IgG. Production of RF is a characteristic feature of rheumatoid arthritis (RA) and is detectable in high titer in about 90% of these patients. In this study, we measured total IgM, IgA, IgMRF and IgARF in serum and synovial fluid of 45 RA patients by ELISA and the results were compared with those obtained b...
متن کاملDisease-modifying Antirheumatic Drugs (DMARDs)
Therapy with disease-modifying antirheumatic drugs (DMARDs) should be started as soon as the diagnosis of rheumatoid arthritis (RA) is made. [1]The early use of DMARDs has been recommended in recent years to reduce disease progression and long-term disability. [2]The need for early use of DMARDs is incorporated in new National Institute for Health and Care Excellence (NICE) guidance. [3]Early u...
متن کاملDisease-modifying Antirheumatic Drugs (DMARDs)
Therapy with disease-modifying antirheumatic drugs (DMARDs) should be started as soon as the diagnosis of rheumatoid arthritis (RA) is made. [1]The early use of DMARDs has been recommended in recent years to reduce disease progression and long-term disability. [2]The need for early use of DMARDs is incorporated in new National Institute for Health and Care Excellence (NICE) guidance. [3]Early u...
متن کاملDisease-modifying Antirheumatic Drugs (DMARDs)
Therapy with disease-modifying antirheumatic drugs (DMARDs) should be started as soon as the diagnosis of rheumatoid arthritis (RA) is made. [1]The early use of DMARDs has been recommended in recent years to reduce disease progression and long-term disability. [2]The need for early use of DMARDs is incorporated in new National Institute for Health and Care Excellence (NICE) guidance. [3]Early u...
متن کامل